EGFR and colorectal carcinoma: Combination Therapies Targeting Feedback Pathways Preclinical and early clinical data suggest that the co-targeting of EGFR or other receptor tyrosine kinases can overcome adaptive resistance to KRAS inhibition, particularly in CRC.